Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CAPR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Deramiocel | Muscular Dystrophies | Phase 3 · NCT05126758 | Active not recruiting |
| Allogeneic Cardiosphere-Derived Cells (C | Duchenne Muscular Dystrophy | Phase 2 · NCT02485938 | Completed |
| CAP-1002 Allogeneic Cardiosphere-Derived | Myocardial Infarction | Phase 1/2 · NCT01458405 | Terminated |
| Cenderitide | Heart Failure | Phase 2 · NCT02359227 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CAPR holds $237.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $30.4M/quarter from operations, an estimated runway of 23.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 47 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CAPR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Nippon Shinyaku Co Ltd 10% owner |
Insider | 7,090,351 | 12.20% | 2024-09-20 |
| Blackrock Inc. | Institution (13F) | 4,145,061 | 7.13% | 2026-06-30 |
| TANG CAPITAL MANAGEMENT, LLC | Institution (13G, 5%+) | 4,099,900 | 7.05% | 2026-06-30 |
| Montanova Capital LLC | Institution (13F) | 4,092,784 | 7.04% | 2026-06-30 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Institution (13G, 5%+) | 3,417,891 | 5.88% | 2026-02-19 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 3,397,241 | 5.84% | 2026-06-30 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 3,014,183 | 5.18% | 2026-07-27 |
| Millennium Management LLC | 5%+ holder (13G) | 2,943,086 | 5.06% | 2026-09-08 |
| Vanguard Capital Management LLC | Institution (13F) | 2,297,674 | 3.95% | 2026-06-30 |
| Goldman Sachs Group Inc | Institution (13F) | 1,578,131 | 2.71% | 2026-06-30 |
| Boxer Capital Management, LLC | Institution (13F) | 1,395,156 | 2.40% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 1,372,286 | 2.36% | 2026-06-30 |
Share count 58,138,989 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-06-24 filed 2026-06-24 |
Bergmann Anthony |
Sale (S) | 400 | $30.00 | 11,223 |
| 2026-06-24 filed 2026-06-24 |
Bergmann Anthony |
Option exercise (M) | 400 | – | – |
| 2026-06-24 filed 2026-06-24 |
Krasney Karen |
Option exercise (M) | 400 | $3.18 | 30,947 |
| 2026-06-24 filed 2026-06-24 |
Krasney Karen |
Sale (S) | 400 | $30.00 | 30,547 |
| 2026-06-24 filed 2026-06-24 |
Krasney Karen |
Option exercise (M) | 400 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-08-22 | Deramiocel | BLA | -68.3% | — | — |
| 2025-08-31 | Deramiocel | BLA | -23.2% | +0.8% | +1.1% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CAPR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →